The effect of Epstein-Barr virus viremia on the progression to severe COVID-19.

Autor:	Im JH; Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea., Nahm CH; Department of Laboratory Medicine, Inha University School of Medicine, Incheon, Republic of Korea., Je YS; Department of Laboratory Medicine, Seoul Clinical Laboratories (SCL), Yongin, Republic of Korea., Lee JS; Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea., Baek JH; Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea., Kwon HY; Division of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea., Chung MH; Department of Internal Medicine, Seogwipo Medical Center, Jeju-do, Republic of Korea., Jang JH; Department of Hospital Medicine, Inha University School of Medicine, Incheon, Republic of Korea., Kim JS; Division of Critical Care Medicine, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea., Lim JH; Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea., Park MH; Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2022 May 06; Vol. 101 (18), pp. e29027. Date of Electronic Publication: 2022 May 06.
DOI:	10.1097/MD.0000000000029027
Abstrakt:	Abstract: Epstein-Barr virus (EBV) is frequently reactivated by coronavirus 2019 (COVID-19), and a high incidence of EBV viremia has been reported in patients with severe COVID-19. However, the impact of EBV viremia on progression to severe COVID-19 is unclear. Therefore, we conducted a study to evaluate the effect of EBV on COVID-19 progression.We investigated EBV viremia at the time of admission in COVID-19 patients hospitalized between February 1, 2020, and April 11, 2021. A cross-sectional study was performed to compare the severity of COVID-19 according to the presence or absence of EBV viremia. However, since it is difficult to analyze the influence of EBV viremia on COVID-19 progression with cross-sectional studies, a retrospective cohort study, limited to patients with mild COVID-19, was additionally conducted to observe progression to severe COVID-19 according to the presence or absence of EBV viremia.Two hundred sixty-nine COVID-19 patients were tested for EBV viremia. In a cross-sectional study that included patients with both mild and severe COVID-19, the EBV viremia group had more severe pneumonia than the EBV-negative group. However, in the cohort study limited to mild cases (N = 213), EBV viremia was not associated with COVID-19 progression.COVID-19 severity may affect EBV viremia; however, there was no evidence that EBV viremia was a factor in exacerbating pneumonia in patients with mild COVID-19. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu